Incyte (INCY) Stock – Key Fundamentals Review

By Blake Campbell • Wednesday, July 03 07:51 • Permanent Link

One of the losers of today's trading session was Incyte. Shares of the Biotechnology company plunged -3.0%, and some investors may be wondering if its price of $59.02 would make a good entry point. Here's what you should know if you are considering this investment:

Incyte has moved -6.3% over the last year, and the S&P 500 logged a change of 23.9%
INCY has an average analyst rating of buy and is -17.88% away from its mean target price of $71.87 per share
Its trailing earnings per share (EPS) is $3.3
Incyte has a trailing 12 month Price to Earnings (P/E) ratio of 17.9 while the S&P 500 average is 27.65
Its forward earnings per share (EPS) is $5.34 and its forward P/E ratio is 11.1
The company has a Price to Book (P/B) ratio of 2.46 in contrast to the S&P 500's average ratio of 4.59
Incyte is part of the Health Care sector, which has an average P/E ratio of 27.53 and an average P/B of 3.61
INCY has reported YOY quarterly earnings growth of 670.5% and gross profit margins of 0.5%
The company has a free cash flow of $977.97 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.